Skip to content

Author

A. A. Malik

We have 7 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Transradial versus transfemoral access for diagnostic cerebral angiography: a systematic review and meta-analysis of 32 studies.

OBJECTIVE To compare the safety, efficacy, and patient-centered outcomes of transradial access (TRA) versus transfemoral access (TFA) in patients undergoing diagnostic cerebral angiography. METHODS PubMed, Embase, and Scopus were searched from inception through April 2026. RCTs and observational studies comparing TRA...

A. A. Malik, Goodluck Oparaugo, Sajjad Khan et al. · 0 citations
Review Open access Oct 2026

Efficacy and Safety of CAR T‐Cell Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review and Meta‐Analysis

Patients with relapsed or refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) have limited treatment options and poor outcomes. CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has shown promising activity in this setting; however, the available e...

Anfal Khan, A. A. Malik, Waqas Kareem et al. · 0 citations
Review Aug 2026

Efficacy and safety of carboplatin-containing chemotherapy in triple-negative breast cancer: A comprehensive systematic review, meta-analysis, and trial sequential analysis with BRCA/HRD subgroup assessment.

BackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options. Platinum agents, particularly carboplatin's DNA damaging properties suggest efficacy, its impact on survival outcomes and toxicity remains uncertain.MethodsPubMed, Embase, Scopus, Cochrane Library, and Clini...

M. Amjad, M. Bashir, Khwaja Waleed Maqbool et al. · 0 citations
Review Sep 2026

Clinical Outcomes of Sacituzumab Govitecan in Breast Cancer: A Systematic Review, Meta-Analysis, and GRADE Assessment of Randomized Evidence.

OBJECTIVES Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate delivering SN-38, has shown promising activity in advanced breast cancer. However, variability across trials and inclusion of nonrandomized data in prior meta-analyses limit the certainty of its efficacy and safety. This study aimed to eva...

M. Amjad, M. Rafique, S. F. Hussain et al. · 0 citations
Review Open access Sep 2026

Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Reduced or Mildly Reduced Ejection Fraction: A GRADE‐Assessed Systematic Review and Meta‐Analysis

Catheter ablation was associated with lower mortality and improved cardiac function compared with medical therapy in patients with AF and HFrEF/HFmrEF and further studies specifically evaluating HFmrEF populations are warranted.

A. A. Malik, Nasir Saeed, Goodluck Oparaugo et al. · 0 citations
Review Open access Aug 2026

Impact of balloon guide catheter versus conventional guide catheter on technical and clinical outcomes in mechanical thrombectomy for acute ischemic stroke: a systematic review and meta-analysis

Findings do not support a recommendation for or against routine BGC use pending confirmatory randomised evidence, and BGC use during EVT is associated with higher excellent functional recovery and first-pass recanalization.

Hunain Shahbaz, A. A. Malik, Mariya Khan et al. · 0 citations
Review Jul 2026

Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis.

Baxdrostat, particularly at 2 mg, provides clinically meaningful BP reductions, and serious safety outcomes remain entirely comparable to control, which highlights a reassuring safety profile.

B. Khan, Muhammad Yahya, H. Khan et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.